Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Amediplase. Menarini.

Sheila A Doggrell1

  • 1Doggrell Biomedical Communications, 47 Caronia Crescent, Lynfield, Auckland, New Zealand. s_doggrell@yahoo.com

Current Opinion in Investigational Drugs (London, England : 2000)
|April 16, 2004
PubMed
Summary

Amediplase, a novel chimeric protein, is being developed for thrombosis treatment. Clinical trials were ongoing as of June 2002.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much?

Expert opinion on investigational drugs·2026
Same author

Is supplemental vitamin D useful in the clinically isolated syndrome (CIS) typical of multiple sclerosis?

Expert opinion on pharmacotherapy·2026
Same author

Is seltorexant, an orexin-2 receptor antagonist, showing promise in insomnia?

Expert opinion on investigational drugs·2026
Same author

Does varenicline promote abstinence in youths who vape?

Expert opinion on pharmacotherapy·2025
Same author

Reply to: reframing guselkumab's benefit in ulcerative colitis: insights from QUASAR and emerging evidence.

Expert opinion on biological therapy·2025
Same author

With guselkumab, does the dual mechanisms to inhibit IL-23, help in ulcerative colitis?

Expert opinion on biological therapy·2025

Area of Science:

  • Biochemistry
  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Thrombosis poses a significant health risk, necessitating effective therapeutic agents.
  • Current treatments for thrombosis have limitations, driving the need for novel solutions.
  • Amediplase combines functional domains of tissue plasminogen activator and pro-urokinase plasminogen activator.

Purpose of the Study:

  • To evaluate the efficacy and safety of amediplase for treating thrombosis.
  • To advance amediplase through clinical development stages.

Main Methods:

  • Development of amediplase, a chimeric protein.
  • Conducting Phase III clinical trials to assess therapeutic potential.

Main Results:

  • Phase III trials for amediplase were in progress by June 2002.
  • Data on efficacy and safety from these trials were pending.

Conclusions:

  • Amediplase represents a promising therapeutic candidate for thrombosis.
  • Further clinical data will determine the ultimate role of amediplase in patient care.

Related Experiment Videos